PMID- 33880111
OWN - NLM
STAT- MEDLINE
DCOM- 20211223
LR  - 20211223
IS  - 1555-4317 (Electronic)
IS  - 1555-4309 (Print)
IS  - 1555-4309 (Linking)
VI  - 2021
DP  - 2021
TI  - Multiparameter Analysis Using (18)F-FDG PET/CT in the Differential Diagnosis of 
      Pancreatic Cystic Neoplasms.
PG  - 6658644
LID - 10.1155/2021/6658644 [doi]
LID - 6658644
AB  - PURPOSE: To evaluate multiparametric analysis in differential diagnosis between 
      pancreatic serous cystic neoplasms (SCNs) and mucinous cystic neoplasms (MCNs) as 
      well as the differentiation of the benign and malignant MCNs with (18)F-FDG 
      (18-fluorodeoxyglucose) PET/CT (positron emission tomography). METHODS: Forty 
      patients with total of 41 lesions (SCNs: 27/41; MCNs: 14/41), who were 
      preoperatively examined with (18)F-FDG PET/CT, were retrospectively analyzed. 
      Multiple quantitative parameters using conventional and texture features were 
      included. The combined model was established with complementary PET/MR 
      parameters. The differential diagnostic efficacy of each independent parameter 
      and the combined model were evaluated with receiver operating characteristic 
      (ROC) analysis. Integrated discriminatory improvement (IDI) and net 
      reclassification improvement (NRI) were used to evaluate improvement of 
      diagnostic efficacy by using combination of multiple parameters. RESULTS: Among 
      all independent parameters, the percentile 5th (0.88 +/- 0.38 vs 0.47 +/- 0.23, P < 
      0.001) showed the highest discriminative diagnostic value. The combination of 
      multiple parameters can improve the differential diagnostic efficacy of SCNs and 
      MCNs (sensitivity = 71.4%, specificity = 77.8%, and AUC = 0.788), and the 
      addition of texture parameters to the conventional parameters allowed a 
      significant reclassification with IDI = 0.236 (95% CI: 0.095-0.377) and 
      categorical NRI = 0.434 (95% CI: 0.030-0.838). SURmax (tumor to normal pancreas 
      ratio, T/P) and SURmax (tumor to aorta ratio, T/A) both showed the highest 
      discriminative diagnostic value (sensitivity = 100.0%, specificity = 70.0%, 
      AUC = 0.900, and Youden index = 0.700) in the differential diagnosis of benign 
      and malignant MCNs, with the cutoff values of 0.84 and 0.90, respectively. 
      CONCLUSION: Combination of multiple parameters using (18)F-FDG PET/CT could 
      further improve differentiation between pancreatic SCNs and MCNs. SURmax (T/P) 
      and SURmax (T/A) could improve differential diagnosis of benign and malignant 
      MCNs.
CI  - Copyright (c) 2021 Guanyun Wang et al.
FAU - Wang, Guanyun
AU  - Wang G
AUID- ORCID: 0000-0003-1880-7163
AD  - Department of Nuclear Medicine, The First Medical Centre, Chinese PLA General 
      Hospital, Fuxing Road 28, Beijing 100853, China.
AD  - Medical School of Chinese PLA, Fuxing Road 28, Beijing 100853, China.
FAU - Dang, Haodan
AU  - Dang H
AD  - Department of Nuclear Medicine, The First Medical Centre, Chinese PLA General 
      Hospital, Fuxing Road 28, Beijing 100853, China.
FAU - Yu, Peng
AU  - Yu P
AD  - Department of Nuclear Medicine, The First Medical Centre, Chinese PLA General 
      Hospital, Fuxing Road 28, Beijing 100853, China.
FAU - Liu, Honghong
AU  - Liu H
AD  - Department of Nuclear Medicine, The First Medical Centre, Chinese PLA General 
      Hospital, Fuxing Road 28, Beijing 100853, China.
FAU - Wu, Yue
AU  - Wu Y
AD  - Diagnostic Imaging, Siemens Healthineers Ltd., Beijing 100102, China.
FAU - Yao, Shulin
AU  - Yao S
AD  - Department of Nuclear Medicine, The First Medical Centre, Chinese PLA General 
      Hospital, Fuxing Road 28, Beijing 100853, China.
FAU - Tian, Jiahe
AU  - Tian J
AD  - Department of Nuclear Medicine, The First Medical Centre, Chinese PLA General 
      Hospital, Fuxing Road 28, Beijing 100853, China.
FAU - Ye, Huiyi
AU  - Ye H
AD  - Department of Radiology, The First Medical Centre, Chinese PLA General Hospital, 
      Fuxing Road 28, Beijing 100853, China.
FAU - Xu, Baixuan
AU  - Xu B
AUID- ORCID: 0000-0002-6550-4758
AD  - Department of Nuclear Medicine, The First Medical Centre, Chinese PLA General 
      Hospital, Fuxing Road 28, Beijing 100853, China.
LA  - eng
PT  - Journal Article
DEP - 20210407
PL  - England
TA  - Contrast Media Mol Imaging
JT  - Contrast media & molecular imaging
JID - 101286760
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Adult
MH  - Cystadenoma, Mucinous/*diagnosis/diagnostic imaging/pathology
MH  - Cystadenoma, Serous/*diagnosis/diagnostic imaging/pathology
MH  - Diagnosis, Differential
MH  - Female
MH  - Fluorodeoxyglucose F18/administration & dosage
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multimodal Imaging
MH  - Pancreatic Cyst/complications/*diagnosis/diagnostic imaging/pathology
MH  - Pancreatic Neoplasms/complications/*diagnosis/diagnostic imaging/pathology
MH  - *Positron Emission Tomography Computed Tomography
MH  - Radiopharmaceuticals/administration & dosage
PMC - PMC8046553
COIS- Yue Wu was employed by Siemens Healthineers Ltd. The remaining authors declare 
      that the research was conducted in the absence of any commercial or financial 
      relationships that could be construed as a potential conflict of interest.
EDAT- 2021/04/22 06:00
MHDA- 2021/12/24 06:00
PMCR- 2021/04/07
CRDT- 2021/04/21 06:41
PHST- 2020/12/25 00:00 [received]
PHST- 2021/03/20 00:00 [revised]
PHST- 2021/03/24 00:00 [accepted]
PHST- 2021/04/21 06:41 [entrez]
PHST- 2021/04/22 06:00 [pubmed]
PHST- 2021/12/24 06:00 [medline]
PHST- 2021/04/07 00:00 [pmc-release]
AID - 10.1155/2021/6658644 [doi]
PST - epublish
SO  - Contrast Media Mol Imaging. 2021 Apr 7;2021:6658644. doi: 10.1155/2021/6658644. 
      eCollection 2021.